CMS has revealed a new, voluntary access programme that aims to broaden the use of GLP-1 agonist medicines for diabetes and obesity.
Sanofi’s last job before breaking up for the Christmas holiday? Putting the finishing touches on a $2.5bn agreement to buy vaccine firm Dynavax.
The FDA approved Agios Pharmaceuticals’ drug mitapivat to treat thalassemia on Tuesday, under the name Aqvesme, following a three-month delay and a missed deadline. The
Companies that have voluntarily agreed to drug pricing deals with the White House appear to be exempt from two new CMS demonstration programs that have
Plus, news about BioMarin and Cassava. 💊 Gilead opts into Assembly Bio’s genital herpes programs: As a result, Gilead will pay Assembly $35 million based
Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday.
Separately, Sanofi said the …
Copyright 2025 dijee Intelligence Ltd. dijee Intelligence Ltd. is a private limited company registered in England and Wales at Media House, Sopers Road, Cuffley, Hertfordshire, EN6 4RY, UK registeration number 16808844